Log in to search using one of your social media accounts:

 

Emergence of breath testing as a new non-invasive diagnostic modality for neurodegenerative diseases.

Emergence of breath testing as a new non-invasive diagnostic modality for neurodegenerative diseases. Brain Res. 2018 Apr 20;: Authors: Subramaniam NS, Bawden CS, Waldvogel H, Faull RML, Howarth GS, Snell RG Abstract Neurodegenerative diseases (NDDs) are incapacitating disorders that result in progressive motor and cognitive impairment. These disease include Alzheimer's disease the most common cause of dementia, frontotemporal dementia, amyotrophic lateral sclerosis, dementia with Lewy bodies, Parkinson's, Huntington's, Friedreich's ataxia, and prion disease. Dementia causing NDDs impose a high social and economic burden on communities around the world. Rapid growth in knowledge regarding the pathogenic mechanisms and disease-associated biomarkers of these diseases in the past few decades have accelerated the development of new diagnostic methods and therapeutic opportunities. Continuous effort is being applied to the development of more advanced, easy-to-apply and reliable methods of diagnosis, that are able to identify disease manifestation at its earliest stages and before clinical symptoms become apparent. Development of such diagnostic tools are essential in aiding effective disease management through accurate monitoring of disease progression, timely application of therapeutics and evaluation of treatment efficacy. Recently, several studies have identified novel biomarkers based on compounds in exhaled breath associated with specific NDDs. The use ...
Source: Brain Research - Category: Neurology Authors: Tags: Brain Res Source Type: research

Related Links:

DEMENTIA signs and symptoms include memory loss, confusion in conversations and losing interest in hobbies. There are several different types of the condition including dementia with lewy bodies and vascular dementia. Alzheimer ’s disease is the most common form of the disease. This is how long you could live if you have the condition, according to the Alzheimer’s Society.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Papadimas GK, Paraskevas GP, Zambelis T, Karagiaouris C, Bourbouli M, Bougea A, Walter MC, Schumacher NU, Krause S, Kapaki E Abstract VCP-proteinopathy is a multisystem neurodegenerative disorder caused by mutations in valosin containing protein. Here, we report the first Greek case of VCP-proteinopathy in a 62 year old patient with a slowly progressing muscular weakness since his mid-40s and a severe deterioration during the last year. He also manifested dementia with prominent neuropsychiatric symptoms, including aggression, apathy, palilalia and obsessions. Brain MRI revealed frontal atrophy, while musc...
Source: Acta Myologica - Category: Neurology Tags: Acta Myol Source Type: research
Authors: Sauerbier A, Aris A, Lim EW, Bhattacharya K, Ray Chaudhuri K Abstract Parkinson disease (PD) affects people of all races and ethnicity worldwide. PD is a multineurotransmitter and multisystem disorder and our current concept of the natural history of PD has changed considerably over the past decades. Many aspects of this heterogeneous condition still remain unexplained; one aspect that is poorly studied is the role of ethnicity and manifest motor and non-motor PD. Some preliminary data suggest that the prodromal risk of developing PD, clinical symptom expression and the experience of living with the condit...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Authors: Titova N, Chaudhuri KR Abstract Most patients with Parkinson disease (PD) have non-motor symptoms (NMS), and on average these can range from four to 19 different symptoms. NMS dominate the prodromal phase of PD and some may serve as clinical biomarkers of PD. NMS can be dopaminergic, non-dopaminergic, of genetic origin or drug induced. Clinical assessment of NMS should include the NMS Questionnaire (completed by patients) for screening, as recommended by the International Parkinson and Movement Disorders Society and other international societies. The total number of NMS in a patient with PD constitutes the...
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Authors: Piguet O PMID: 29764349 [PubMed - in process]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
James Parkinson's Essay on the shaking palsy, 1817-2017. Med J Aust. 2018 May 21;208(9):384-386 Authors: Toodayan N PMID: 29764348 [PubMed - in process]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Authors: Chew EG, Foo JN, Tan EK PMID: 29764346 [PubMed - in process]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
Conclusions: In this review we will provide animal and human research data on the current clinical neurological uses for CBD individually and in combination with Δ9-THC. We will emphasize the neuroprotective, antiinflammatory, and immunomodulatory benefits of phytocannabinoids and their applications in various clinical syndromes. PMID: 29770251 [PubMed]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research
Authors: Prasad Tharanga Jayasooriya RG, Dilshara MG, Neelaka Molagoda IM, Park C, Park SR, Lee S, Choi YH, Kim GY Abstract In the present study, we report that camptothecin (CPT) caused irreversible cell cycle arrest at the G2/M phase, and was associated with decreased levels of cell division cycle 25C (Cdc25C) and increased levels of cyclin B1, p21, and phospho-H3. Interestingly, the reactive oxygen species (ROS) inhibitor, glutathione, decreased CPT-induced G2/M phase arrest and moderately induced S phase arrest, indicating that the ROS is required for the regulation of CPT-induced G2/M phase arrest. Furthermore...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Discussions: Address ACP Process in PACEMary Naber, MBA, Southeast Michigan PACE 3:20 pm-3:40 pm                    Small Group Report-out: Return and ReportDr. Graddy-Dansby, Southeast Michigan PACE 3:40 pm-4:00 pm                    Discuss Next StepsMary Naber, MBA, Southeast Michigan PACEThursday, October 11, 2018 8:00 am                                   Registration for conference opensLight breakfast options 8:30 am&nbs...
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care syndicated Source Type: blogs
More News: ALS | Alzheimer's | Ataxia | Brain | Dementia | Friedreich's Ataxia | Huntington's Disease | Neurology | Parkinson's Disease | Study